PLEASE NOTE: To reply to any of the postings to this Topic, "Requests Prior to 07 March 2007," please contact: 

---

---

Novartis Research Study—Posted 6 March 2007
Participants sought for a Novartis research study designed to evaluate the safety and tolerability of switching from donepezil to an initial dose of 5cm2 rivastigmine patch formulation in patients with probable Alzheimer disease (MMSE 10-24). View this and additional information on this study at www.clinicaltrials.gov, ID# NCT00428389.

---

Senile Plaque Imaging Study in Patients with Alzheimer's Disease Using Positron Emission Tomography—Posted 5 January 2007
This study takes place one time at the PET Centre located at the Centre for Addiction and Mental Health Clarke site (Toronto, Canada). After injecting the tracer (a chemical substance) via a vein in your arm, you will lie down in the PET scanner for a maximum of 2 hours, as the PET scan images the tracer as it enters your brain. During this time, about 10 blood samples of 10 mL each will be drawn from you via an IV. Thus, for those samples a needle will be placed only once. Your caregiver may be present throughout the study. You may take part in up to three PET studies using three different beta-amyloid tracers. See more details.

Directory of Research Opportunities for People with Dementia and Their Families—Posted 29 December 2006
Compiled by the Massachusetts Chapter of the Alzheimer's Association, this resource lists studies in Massachusetts that are seeking patients and caregivers to participate in research on basic science of AD, new treatments, improved caregiving, caregiver stress, etc. See more details.

---

Alzheimer's Disease Sibling Study, University of Michigan—Posted 6 December 2006
The purpose of this is to study the impact of early-onset Alzheimer's disease on families. In general, most of the research on coping with Alzheimer's disease has focused on the patient or the primary caregiver. This study will explore how a person's life is impacted when a sibling has or has had Alzheimer's disease.

You may participate if your brother or sister was under the age of 65 when their symptoms of Alzheimer's disease began, and if you are not experiencing any symptoms of Alzheimer's disease yourself. Recruitment will continue until February 2007.

We will mail you a confidential questionnaire that will take approximately 30-40 minutes to complete. This will help us learn about your attitudes regarding Alzheimer's disease and the impact that your sibling's illness has had on your life. It is possible for questionnaires to be sent to you by email if that is more convenient. Each participant will receive a packet of Alzheimer's disease information and resources. You will also have the opportunity to participate in an optional telephone interview. Individuals who complete both the questionnaire and the interview will receive an additional $10 gift card. This study has been approved by the University of Michigan Institutional Review Board.

This study is designed to help the medical community provide educational and supportive resources and services to families touched by Alzheimer's disease and may lead to improved healthcare, mental healthcare, and communication for the members of a family. Please contact Karen Knutson at 734-546-2200, or by e-mail at karenkn@umich.edu.

---

Seeking Research Participants—Posted 11 July 2005
Would you like to help with scientific discoveries of Alzheimer disease? Ever wonder what your brain looks like? Participants needed for a University of Florida functional magnetic resonance imaging (fMRI) study looking at language functions in the brain. To participate you must be right-handed, a native English speaker, diagnosed with Alzheimer's disease, able to talk to others and follow instructions. Participation time is approximately 2 hours and you will be emailed pictures of your brain. You cannot participate if you have claustrophobia, a cardiac pacemaker, or metal implants other than dental work. Please call (352) 273-5249 if interested.

---

Alzheimer's Disease Clinical Trial—Posted 13 February 2005
Seeking individuals with mild to moderate symptoms of Alzheimer’s disease to participate in a 24-week research study. Alzheimer's disease is the most common form of dementia, accounting for approximately 50 percent of patients in the United States with progressive cognitive decline. More than 3.5 million people in the United States have Alzheimer's disease. With the aging of the population, this number continues to grow each year. We are conducting a clinical trial designed to demonstrate whether or not a novel investigational medication alleviates the symptoms associated with Alzheimer's disease. See more details.

---

Seeking Research Participants—Posted 18 October 2004
The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.

---

Seeking Research Participants—Posted 25 May 2004
Identification of factors that keep individuals with Alzheimer’s disease (AD) from functioning at an optimal level in their daily lives is of singular importance. Most aspects of visual cognition and memory are impaired in AD, including the abilities to recognize and discriminate objects, faces, words, and other patterns. Recent research indicates that deficits in basic vision are prevalent in this disorder and can strongly predict impairments in visual cognition, suggesting that basic vision may be a logical point of non-pharmacological intervention for improving cognition in AD. See more details.

---

Seeking Research Participants—Posted 3 May 2004
GenoMed believes that angiotensin II, a well-known hormone, may contribute to the inflammation and destruction of nerves that occurs near piles of amyloid in the brain. In other words, ACE inhibitors or angiotensin II receptor blockers (ARBs), two classes of extremely safe drugs which have been in widespread clinical use to treat blood pressure for over two decades, might be useful in Alzheimer's Disease. To enroll in our free clinical trial, please contact David W. Moskowitz MD FACP, Chief medical officer & CEO, GenoMed, Inc., 909 South Taylor Ave., St. Louis, MO 63110, email: dwmoskowitz@genomedics.com, tel. 314-977-0115.